Myriad Genetics Inc
(NAS:MYGN)
$
22.25
0.29 (1.32%)
Market Cap: 2.02 Bil
Enterprise Value: 2.04 Bil
PE Ratio: 0
PB Ratio: 2.73
GF Score: 81/100 
Myriad Genetics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021 / 12:50PM GMT
Release Date Price:
$29.3
(+0.24%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, everyone, and welcome to the third and final day of the Goldman Sachs Healthcare Conference. I'm Matt Sykes, the Senior Life Sciences Tools & Diagnostics analyst here at Goldman. And we have the pleasure of welcoming Myriad Genetics' management team here. We have Paul Diaz, the President and Chief Executive Officer; and Bryan Riggsbee, the Chief Financial Officer.
Paul, Bryan, thanks so much for being with us today.
Paul J. Diaz
Myriad Genetics, Inc. - CEO, President & Director
Thank you, Matt.
R. Bryan Riggsbee
Myriad Genetics, Inc. - Executive VP, CFO & Treasurer
Thanks for having us.
Questions & Answers
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
Great. Maybe, Paul, I'll turn it over to you first and kind of let you set the stage and just go over a couple of the key highlights for investors
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers